Today: 11 June 2026
Salesforce stock (CRM) drops 4% as 2026 opens; investors eye jobs report and next earnings
3 January 2026
1 min read

Salesforce stock (CRM) drops 4% as 2026 opens; investors eye jobs report and next earnings

NEW YORK, January 2, 2026, 17:50 ET — After-hours

  • Salesforce shares fell about 4.3% to $253.62, underperforming broader U.S. indexes.
  • The Dow finished higher, but Salesforce’s decline weighed on the price-weighted index early.
  • Next catalysts include the Jan. 9 U.S. jobs report and Salesforce’s late-February earnings update.

Salesforce, Inc. shares were down 4.3% at $253.62 in after-hours trade on Friday, after moving between $252.49 and $267.00 during the session, according to market data.

The slide put pressure on a large-cap software name that investors often use as a read on corporate IT budgets and the pace of enterprise adoption of new tools, including generative AI.

It also mattered for the Dow, which is price-weighted — meaning higher-priced stocks have a bigger impact on the index than lower-priced ones. MarketWatch data showed Salesforce and Travelers were the biggest drags early in the session.

U.S. stocks ended mixed on the first trading day of 2026, with the Dow and S&P 500 up while the Nasdaq edged lower, as gains in chipmakers offset weakness in several large technology names. Joe Mazzola, head of trading & derivatives strategist at Charles Schwab, described the mood as “buy the dip, sell the rip.” Reuters

Other enterprise software shares also fell, with ServiceNow down about 3.8% while Oracle was slightly higher, MarketWatch reported.

Salesforce has faced heightened scrutiny over how quickly AI features translate into durable growth, even as companies continue to spend on cloud software to modernize operations.

In December, Salesforce raised its fiscal 2026 revenue outlook to $41.45 billion to $41.55 billion and lifted its adjusted profit forecast, citing rising adoption of its AI products. CEO Marc Benioff said Agentforce and Data 360 were running at nearly $1.4 billion in annual recurring revenue (ARR), an annualized measure of subscription sales.

The next major company-specific checkpoint is earnings. Salesforce is estimated to report results around Feb. 25, according to Nasdaq’s earnings calendar.

Investors will be looking for updates on subscription demand, margins and the pace of AI monetization — along with any changes to full-year guidance and capital return.

Macro catalysts are also stacking up quickly. Reuters’ week-ahead schedule flagged the U.S. employment report due Jan. 9 and the consumer price index report due Jan. 13, alongside the start of fourth-quarter earnings season.

For software stocks such as Salesforce, a hotter inflation or jobs print can matter because it can change expectations for interest rates, which in turn affects valuations for growth-oriented shares.

Traders will be watching whether early-year dip buying shows up after Friday’s pullback, or whether investors stay selective until the next round of data and earnings sets the tone for 2026.

Stock Market Today

  • AMD Stock Price Forecast: Analyst Lowers Target Amid AI Market Caution
    June 11, 2026, 11:00 AM EDT. Shares of Advanced Micro Devices (AMD) have surged 111% year-to-date, driven by investor optimism over its expanding role in the artificial intelligence (AI) sector. Despite the strong performance, a prominent AI-focused analyst has trimmed the price target for AMD, signaling caution about the chipmaker's near-term prospects. The analyst cited concerns over competitive pressures and potential market saturation. AMD's growth is largely tied to its ability to capture demand in AI computing, a fast-evolving field requiring specialized semiconductor technology. Investors are weighing the company's robust sales against risks from supply chain constraints and intensifying industry competition.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention
Previous Story

Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention

Shopify stock slides after Canadian court order in CRA data dispute
Next Story

Shopify stock slides after Canadian court order in CRA data dispute

Go toTop